Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Not Confirmed
Not Confirmed
11-13 November, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
11-14 November, 2024
The Pharmacy Technolog...The Pharmacy Technology
Industry Trade Show
Not Confirmed
11-13 November, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities
12 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/curis-announces-initial-combination-study-data-from-its-takeaim-lymphoma-study-302012478.html
11 Dec 2023
// PRESS RELEASE
https://investors.curis.com/2023-12-11-Curis-Presented-Clinical-Data-from-the-TakeAim-Leukemia-Study-at-the-2023-ASH-Conference
06 Dec 2023
// PRESS RELEASE
https://investors.curis.com/2023-12-06-Curis-Announces-Three-Presentations-at-ASH
05 Dec 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/curis-enters-into-agreement-for-emavusertib--pembrolizumab-combination-study-in-melanoma-302005577.html
02 Nov 2023
// PRESS RELEASE
https://investors.curis.com/2023-11-02-Curis-Provides-Third-Quarter-2023-Business-Update
07 Jul 2023
// Paul Schloesser ENDPTS
https://endpts.com/fda-lifts-partial-hold-on-curis-phi-ii-leukemia-study-as-biotech-raises-15m/
Details:
CA-4948 (emavusertib) is an IRAK4/FLT3/CLK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with Refractory Primary Central Nervous System Lymphoma.
Lead Product(s): Emavusertib,Ibrutinib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2023
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
Details : CA-4948 (emavusertib) is an IRAK4/FLT3/CLK inhibitor small molecule drug candidate, which is currently being evaluated for the treatment of patients with Refractory Primary Central Nervous System Lymphoma.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 12, 2023
Details:
Under the terms of the agreement, Curis will supply emavusertib and Merck will supply pembrolizumab & bear the costs for clinical study of the novel combination of CA-4948 (emavusertib) and pembrolizumab (anti-PD1) in metastatic melanoma.
Lead Product(s): Emavusertib,Pembrolizumab
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: University of Florida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 05, 2023
Lead Product(s) : Emavusertib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : University of Florida
Deal Size : Undisclosed
Deal Type : Agreement
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
Details : Under the terms of the agreement, Curis will supply emavusertib and Merck will supply pembrolizumab & bear the costs for clinical study of the novel combination of CA-4948 (emavusertib) and pembrolizumab (anti-PD1) in metastatic melanoma.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 05, 2023
Details:
Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Cantor Fitzgerald & Co.
Deal Size: $15.1 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 06, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Cantor Fitzgerald & Co.
Deal Size : $15.1 million
Deal Type : Public Offering
Curis Announces $15.1 Million Registered Direct Offering
Details : Curis intends to use the net proceeds from the offering on research and development of CA-4948 (emavusertib), an Oral, small molecule IRAK4 kinase inhibitor, being developed for the treatment of Leukemia.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 06, 2023
Details:
CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID
Details : CA-4948 (emavusertib) is a triple target inhibitor (IRAK4, FLT3 and CLK), which is investiated for patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2023
Details:
With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of CA-4948 (emavusertib).
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Aurigene
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Aurigene
Deal Size : Not Applicable
Deal Type : Not Applicable
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
Details : With the partial hold, FDA is requesting additional data from the study, including data related to the death of R/R AML patient who experienced, among several conditions, rhabdomyolysis, which has previously been identified as a dose-limiting toxicity of...
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 04, 2023
Details:
Emavusertib (CA-4948) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Lead Product(s): Emavusertib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Lead Product(s) : Emavusertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Emavusertib (CA-4948) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 30, 2022
Details:
CA-4948 (emavusertib) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
Details : CA-4948 (emavusertib) is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Details:
CA-4948 (emavusertib), is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Lead Product(s): Emavusertib,Azacitidine
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: University of Florida
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Lead Product(s) : Emavusertib,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : University of Florida
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CA-4948 (emavusertib), is an IRAK4 kinase inhibitor and IRAK4 plays an essential role in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways, which are frequently dysregulated in patients with cancer.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2022
Details:
TakeAim Lymphoma data for the combination of CA-4948 (emavusertib) plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses.
Lead Product(s): Emavusertib,Ibrutinib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2022
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TakeAim Lymphoma data for the combination of CA-4948 (emavusertib) plus ibrutinib show tumor reduction in 8 of 9 evaluable patients, including 2 complete responses and 2 partial responses.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2022
Details:
The data from TakeAim Leukemia study are consistent with our findings demonstrated CA-4948 (emavusertib) encouraging monotherapy activity in patients with R/R AML and MDS including importantly those with spliceosome and FLT3 mutations.
Lead Product(s): Emavusertib,Ibrutinib
Therapeutic Area: Oncology Brand Name: CA-4948
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Lead Product(s) : Emavusertib,Ibrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data from TakeAim Leukemia study are consistent with our findings demonstrated CA-4948 (emavusertib) encouraging monotherapy activity in patients with R/R AML and MDS including importantly those with spliceosome and FLT3 mutations.
Brand Name : CA-4948
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 12, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?